Comparison of Outcomes After Mechanical Thrombectomy Alone or Combined with Intravenous Thrombolysis and Mechanical Thrombectomy for Patients with Acute Ischemic Stroke due to Large Vessel Occlusion. 2018

Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.

BACKGROUND Whether intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) provides additional benefits remains controversial. We aimed to compare clinical and radiologic outcomes between IVT+MT and MT alone groups. METHODS We retrospectively reviewed the clinical and radiological features of patients from the prospectively collected database who sustained anterior circulation stroke due to large vessel occlusion (LVO) and were treated with MT within 8 hours of symptom onset. We compared rates of successful reperfusion, functional independence and mortality at 90 days, and symptomatic intracranial hemorrhage (sICH) as clinical endpoints between the 2 groups. RESULTS The 81 patients included in this study included 38 (46.9%) in the MT alone group (mean age, 72.6 ± 14.1 years; 17 males [44.7%]) and 43 in the IVT+MT group (mean age, 68.9 ± 12.8 years; 29 males [67.4%]). There were no significant differences in patient baseline characteristics between the 2 groups except for a male predominance in the IVT+MT group. The mean interval from onset to groin puncture (221.6 ± 110.5 minutes vs. 204.7 ± 63.7 minutes; P = 0.472) and the rate of successful reperfusion rate (thrombolysis in cerebral infarction 2b/3, 60.5% vs. 58.1%; P = 0.827) did not differ significantly between the MT and IVT+MT groups. The rate of favorable functional outcome, as determined by a modified Rankin Scale score 0-2 (36.8% vs. 51.2%; P = 0.263) and mortality at 90 days (18.4% vs. 9.3%; P = 0.332), and the rate of sICH (5.3% vs. 4.6%; P = 1.000) were also not significantly different between the 2 groups. CONCLUSIONS This study suggests that previous IVT might not facilitate successful reperfusion and favorable functional outcomes in patients with anterior circulation stroke treated with MT. MT alone can be a safe and effective treatment modality in patients who are ineligible for IVT for various reasons.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D005260 Female Females
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies

Related Publications

Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
March 2019, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
January 2025, Frontiers in neurology,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
June 2022, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
January 2022, Frontiers in neurology,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
January 2021, Critical reviews in biomedical engineering,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
May 2021, JAMA,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
January 2021, Frontiers in neurology,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
December 2018, Journal of neurology,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
August 2017, JAMA neurology,
Jai Ho Choi, and Sang Hyuk Im, and Ki Jeong Lee, and Ja Seong Koo, and Bum Soo Kim, and Yong Sam Shin
May 2021, JAMA,
Copied contents to your clipboard!